An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia.
about
Sleep disruption and the sequelae associated with traumatic brain injuryInternational Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.Insomnia pharmacotherapyChronic insomniaDepression and sleep: pathophysiology and treatmentNeurophysiology of sleep and wakefulness: basic science and clinical implicationsUpdate on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary careEvaluation of the efficacy and safety of ramelteon in subjects with chronic insomniaThe melatonin receptor agonist ramelteon effectively treats insomnia and behavioral symptoms in autistic disorderGood night and good luck: norepinephrine in sleep pharmacologyPharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disordersRamelteon: a novel hypnotic indicated for the treatment of insomniaDiagnosis and treatment of chronic insomnia.Melatonin agonists and insomnia.[The newer sedative-hypnotics].Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis.Ramelteon prior to a short evening nap impairs neurobehavioral performance for up to 12 hours after awakening.Melatonin and its receptors: a new class of sleep-promoting agents.Treatment options for insomnia--pharmacodynamics of zolpidem extended-release to benefit next-day performance.Clinical guideline for the evaluation and management of chronic insomnia in adults.Melatonin and melatonergic drugs on sleep: possible mechanisms of action.Insomnia medication use and the probability of an accidental event in an older adult population.Melatonin, the Hormone of Darkness: From Sleep Promotion to Ebola Treatment.Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjectsTherapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.Relationship between reported and measured sleep times: the sleep heart health study (SHHS).Pharmacological Treatment of Insomnia.Ramelteon: a novel treatment for the treatment of insomnia.Emerging pharmacotherapeutic agents for insomnia: a hypnotic panacea?Therapeutic options for sleep-maintenance and sleep-onset insomnia.Critical appraisal of ramelteon in the treatment of insomnia.A review of ramelteon in the treatment of sleep disordersPharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applicationsEffect of ramelteon on middle-of-the-night balance in older adults with chronic insomniaEfficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomniaRamelteon for the treatment of insomnia in menopausal womenThe effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.Ramelteon: a novel approach in the treatment of insomnia.New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists.
P2860
Q23910486-E6E0F0E8-C7CB-47D9-AAEB-81FAFD517E96Q24623433-0AFC1F46-2D3B-45FF-8FF6-776E7BDDEDE1Q24623757-2E6D0DAC-16E8-4F47-95DE-A09D91BF63F7Q24632561-E848CE7F-4C08-4381-8420-E5CC8FA577BAQ24635629-DDA54365-AEF2-4FF0-AF5C-B5AFC768DBC3Q24658243-055498FA-1D8B-4627-BC88-2AC4B0AEF8F2Q24670611-EC7CD33E-BB71-49A2-98BD-2BFEF0000E01Q24683617-BA017C35-B15E-4A95-8690-42BBA2C3DB18Q30436298-41AE06ED-2EFC-40ED-8DA3-8DF7B4EF836EQ33615826-6B693C1D-0C2C-4C90-A509-1094C9557070Q33854026-E9725F46-1EBC-4B04-B640-747960F3A73CQ33894678-5400F7FC-9070-4CEC-B385-4E30A9C0875DQ34075878-5CCA1517-CBDA-41E5-AE9F-69382E1A692CQ34097173-3EB21697-F00D-4E9D-A9FD-C3090FF2F80EQ34143490-356DF08A-7910-46F8-9D03-04578CEE950AQ34381509-102945FD-DB94-4E8D-A111-F9C39E291AA0Q34458240-6C4D3746-0C27-45BD-99FC-F8D75E89BA60Q34682298-89A4C29B-9470-4A70-BDD8-E5A3E5B1448CQ34840661-4F516083-D846-412B-8C4A-C142B19BD401Q34852294-E46AFBA9-589D-4EA6-A4F9-FA2962E548E1Q34970081-D4000D08-FD5F-4FA2-92E0-123D428CC415Q35026469-843763E1-3077-4029-868B-9DF2639EE6D6Q35101395-3245D992-BB7F-4B68-BD50-EAAF81B3F1FEQ35214361-06A72908-0A7E-45D8-AF58-386C51CB319BQ35276597-58C280AF-5750-4194-938C-BA978B621114Q36040915-61A607B1-8B06-4EEF-95B9-4F602FD86DA7Q36099696-DA633D26-8A79-490D-9374-3CA67F175C12Q36251904-DD60B111-9B42-478D-A8C4-D086436A2B3EQ36532135-47360CCD-A60C-4013-B957-C4CBD316FAADQ36573888-7F6ECB98-E1EF-4FB3-B222-B4CA663798DAQ36693857-8A145213-E258-4AD5-8C6C-6662000154B3Q36779840-8F4DB2BC-59CC-4608-AB0F-CD4E4E8FB16FQ36836767-67053B31-6D62-4485-BB57-8EA8E96D406DQ36873916-1C54F1EC-BE3F-486E-8C8F-98C8A952B1BEQ37086861-AA17B549-68F4-4B4A-A7A3-442529C42622Q37109731-7CDEF038-7B4F-48AE-9035-02D8A844FE25Q37157345-C0EFB6F0-263C-45AC-84B5-DD6C135B78D1Q37210115-30374201-E330-404C-A6ED-9F2FB47A8866Q37224126-A18C116D-D0FE-4098-9924-1E33BAFD37EFQ37235719-A6FFC084-A4AD-4BB4-A53E-89AEC49ED4AA
P2860
An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
An efficacy, safety, and dose- ...... with chronic primary insomnia.
@en
An efficacy, safety, and dose- ...... with chronic primary insomnia.
@nl
type
label
An efficacy, safety, and dose- ...... with chronic primary insomnia.
@en
An efficacy, safety, and dose- ...... with chronic primary insomnia.
@nl
prefLabel
An efficacy, safety, and dose- ...... with chronic primary insomnia.
@en
An efficacy, safety, and dose- ...... with chronic primary insomnia.
@nl
P2093
P1433
P1476
An efficacy, safety, and dose- ...... with chronic primary insomnia.
@en
P2093
David Seiden
Gary Zammit
Jeffrey Zhang
Milton Erman
Stephen Sainati
P356
10.1016/J.SLEEP.2005.09.004
P577
2005-11-23T00:00:00Z